Stelara (ustekinumab)

Manufacturer:
Johnson & Johnson
Route of Administration: 
Intravenous, Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website

Approved Indication:

  • treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
  • treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
  • treatment of moderately-to-severely active Crohn’s disease in adults
  • treatment of moderately-to-severely active ulcerative colitis in adults

Conditions:

  • Crohn’s Disease
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Ulcerative Colitis

Therapeutic Area:

  • Dermatology
  • Gastroenterology
  • Rheumatology